Literature DB >> 15341482

Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.

Martin K Safo1, Osheiza Abdulmalik, Richmond Danso-Danquah, James C Burnett, Samuel Nokuri, Gajanan S Joshi, Faik N Musayev, Toshio Asakura, Donald J Abraham.   

Abstract

Naturally occurring five-membered heterocyclic aldehydes, including 5-hydroxymethyl-2-furfural, increase the oxygen affinity of hemoglobin (Hb) and strongly inhibit the sickling of homozygous sickle red blood (SS) cells. X-ray studies of Hb complexed with these compounds indicate that they form Schiff base adducts in a symmetrical fashion with the N-terminal alphaVal1 nitrogens of Hb. Interestingly, two cocrystal types were isolated during crystallization experiments with deoxygenated Hb (deoxyHb): one crystal type was composed of the low-affinity or tense (T) state Hb quaternary structure; the other crystal type was composed of high-affinity or relaxed state Hb (with a R2 quaternary structure). The R2 crystal appears to be formed as a result of the aldehydes binding to fully or partially ligated Hb in the deoxyHb solution. Repeated attempts to crystallize the compounds with liganded Hb failed, except on rare occasions when very few R state crystals were obtained. Oxygen equilibrium, high performance liquid chromatography (HPLC), antisickling, and X-ray studies suggest that the examined heterocyclic aldehydes may be acting to prevent polymerization of sickle hemoglobin (HbS) by binding to and stabilizing liganded Hb in the form of R2 and/or various relaxed state Hbs, as well as binding to and destabilizing unliganded T state Hb. The proposed mechanism may provide a general model for the antisickling effects of aldehyde containing small molecules that bind to N-terminal alphaVal1 nitrogens of Hb. The examined compounds also represent a new class of potentially therapeutic agents for treating sickle cell disease (SCD).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341482     DOI: 10.1021/jm0498001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

1.  Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.

Authors:  Piyusha P Pagare; Mohini S Ghatge; Faik N Musayev; Tanvi M Deshpande; Qiukan Chen; Courtney Braxton; Solyi Kim; Jürgen Venitz; Yan Zhang; Osheiza Abdulmalik; Martin K Safo
Journal:  Bioorg Med Chem       Date:  2018-04-06       Impact factor: 3.641

2.  Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.

Authors:  Cristiane O Renó; Amanda Rodrigues Barbosa; Sara Santos de Carvalho; Melina B Pinheiro; Danyelle Romana Rios; Vanessa F Cortes; Leandro A Barbosa; Hérica L Santos
Journal:  Ann Hematol       Date:  2020-03-12       Impact factor: 3.673

3.  Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.

Authors:  Tanvi M Deshpande; Piyusha P Pagare; Mohini S Ghatge; Qiukan Chen; Faik N Musayev; Jurgen Venitz; Yan Zhang; Osheiza Abdulmalik; Martin K Safo
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-10-02       Impact factor: 7.652

4.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

5.  An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.

Authors:  Abdelsattar M Omar; Osheiza Abdulmalik; Mohini S Ghatge; Yosra A Muhammad; Steven D Paredes; Moustafa E El-Araby; Martin K Safo
Journal:  Biomolecules       Date:  2020-11-02

6.  Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.

Authors:  Osheiza Abdulmalik; Mohini S Ghatge; Faik N Musayev; Apurvasena Parikh; Qiukan Chen; Jisheng Yang; Ijeoma Nnamani; Richmond Danso-Danquah; Dorothy N Eseonu; Toshio Asakura; Donald J Abraham; Jurgen Venitz; Martin K Safo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-10-19

Review 7.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

8.  Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

Authors:  Guoyan G Xu; Piyusha P Pagare; Mohini S Ghatge; Ronni P Safo; Aheema Gazi; Qiukan Chen; Tanya David; Alhumaidi B Alabbas; Faik N Musayev; Jürgen Venitz; Yan Zhang; Martin K Safo; Osheiza Abdulmalik
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

Review 9.  New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?

Authors:  Esther Oder; Martin K Safo; Osheiza Abdulmalik; Gregory J Kato
Journal:  Br J Haematol       Date:  2016-09-08       Impact factor: 6.998

10.  Structure of fully liganded Hb ζ2β2s trapped in a tense conformation.

Authors:  Martin K Safo; Tzu-Ping Ko; Osheiza Abdulmalik; Zhenning He; Andrew H-J Wang; Eric R Schreiter; J Eric Russell
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.